Hemodialysis dose and long-term COVID-19 outcomes – a retrospective cohort study

Skrócona strona pozycji
dc.contributor.authorStepanova, Natalia
dc.contributor.authorRysyev, Andriy
dc.contributor.authorSnisar, Lyudmyla
dc.date.accessioned2024-03-28T19:41:06Z
dc.date.available2024-03-28T19:41:06Z
dc.date.issued2024-03
dc.descriptionThe study protocol was approved by the Ethics Committee of the State Institution “Institute of Nephrology of the National Academy of Medical Sciences”, Kyiv, Ukraine (protocol number: 2-2021, dated April 6, 2021).
dc.description.abstractIntroduction and aim. Long-term outcomes of COVID-19 pose a global challenge, particularly impacting individuals with un derlying health conditions, including those who have undergone hemodialysis (HD). The study aimed to investigate the rela tionship between preexisting dialysis dose, measured by single pool Kt/V (spKt/V), and long-term outcomes of COVID-19 in patients undergoing HD. Material and methods. Demographic, clinical, and laboratory parameters following COVID-19 recovery, and long-term out comes, including the presence of COVID-19 sequelae, hospitalization, and all-cause mortality during a year after COVID-19 were retrospectively analyzed. Results. Out of the 195 patients included, there were 108 males (55.4%) and 87 females (44.6%), with a median age of 56 (44-63) years and a dialysis duration of 49 (31.3–85.2) months. Patients with spKt/V<1.4 had a significantly increased risk of long-term COVID-19 sequelae (HR 9.1, 95% CI: 3.4; 24.6), hospitalization (HR 7.6, 95% CI: 3.9; 14.6), and all-cause mortality (HR 8.5, 95% CI: 2.9; 25.8) within one year after COVID-19 recovery compared with those with spKt/V≥1.4. spKt/V cutoff point of ≤1.3 emerged as a significant risk factor for one-year hospitalization and mortality within our cohort. Conclusion. Suboptimal dialysis dose, as indicated by spKt/V < 1.4, is associated with adverse long-term COVID-19 outcomes in patients undergoing HD. Optimizing dialysis adequacy may mitigate these risks. Further research is needed to validate these f indings and explore interventions to improve outcomes in this vulnerable population.eng
dc.description.sponsorshipThis study was part of an ongoing project, “Exploring the Mechanisms of Development and Identifying Therapeutic Targets for Post-COVID Syndrome in Dialysis Patients” (National Study Registration Number 0122U000144), of the State Institution “Institute of Nephrology of the National Academy of Medical Science of Ukraine,” Kyiv, Ukraine.
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 22, z. 1 (2024), s. 107–116
dc.identifier.doi10.15584/ejcem.2024.1.21
dc.identifier.eissn2544-1361
dc.identifier.urihttps://repozytorium.ur.edu.pl/handle/item/10364
dc.language.isoeng
dc.publisherPublishing Office of the University of Rzeszow
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Poland*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/pl/*
dc.subjectdialysis dose
dc.subjecthemodialysis
dc.subjecthospitalization
dc.subjectlong COVID
dc.subjectmortality
dc.titleHemodialysis dose and long-term COVID-19 outcomes – a retrospective cohort study
dc.typearticle
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
14.hemodialysis_dose_and_long-term_covid-19_outcomes_-.pdf
Rozmiar:
726.2 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.28 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.22, z. 1 (2024)